28
The FDA approved chikungunya vaccine, recombinant (Vimkunya), as the first virus-like particle single-dose vaccine against chikungunya for patients 12 years and older. The vaccine was approved under priority review and was based on 2 phase 3 clinical trials.1
The vaccine was approved under priority review and was based on 2 phase 3 clinical trials. | Image Credit: Daniel CHETRONI | stock.adobe.com
The approval of our chikungunya vaccine is a testament to our unwavering commitment to addressing unmet medical needs and protecting communities worldwide,” Paul Chaplin, president and CEO of Bavarian Nordic, said in a news release. “As climate change…